| |
|
HCV | Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| 1. | Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic |
| |
Am J Prev Med. 2021 May 10;S0749-3797(21)00220-8. doi: 10.1016/j.amepre.2021.03.011.Online ahead of print.
Harvey W Kaufman 1, Lara Bull-Otterson 2, William A Meyer 3rd 3, Xiaohua Huang 3, Mona Doshani 4, William W Thompson 4, Ademola Osinubi 4, Mohammed A Khan 4, Aaron M Harris 4, Neil Gupta 4, Michelle Van Handel 4, Carolyn Wester 4, Jonathan Mermin 4, Noele P Nelson 4
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 6. | Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience |
| |
Am J Gastroenterol. 2021 Jun 1;116(6):1248-1255.doi: 10.14309/ajg.0000000000001147.
Luca Rinaldi 1, Vincenzo Messina 2, Vito Di Marco 3, Vincenzo Iovinella 4, Ernesto Claar 5, Giuseppe Cariti 6, Rodolfo Sacco 7, Massimo De Luca 8, Gaetano Scifo 9, Pietro Gatti 10, Giorgio Barbarini 11, Valeria Pace Palitti 12, Mariano Quartini 13, Paolo Tundo 14, Gianpiero D'Offizi 15, Giustino Parruti 16, Maria Antonietta di Rosolini 17, Giovanni Garrucciu 18, Lucio Cosco 19, Francesco Benanti 20, Giancarlo Gimignani 21, Umberto Vespasiani Gentilucci 22, Francesco Di Lorenzo 23, Maria D'Antò 24, Riccardo Nevola 1, Tommaso Lupia 6, Valerio Rosato 5, Valeria Morbiducci 13, Ilaria Luzzitelli 15, Federica Sozio 16, Marco Di Stefano 9, Emanuela Ciraci 10, Fabio Bulla 19, Riccardo Guarisco 21, Cecilia Cangiano 1, Michele Imparato 25, Paolo Maggi 2, Antonio Ascione 25, Antonio Craxì 3, Antonio Izzi 26
|
|
| |
|
|
| |
| 8. | Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis |
| |
JAMA Psychiatry. 2021 Jun 2;e210976. doi: 10.1001/jamapsychiatry.2021.0976.Online ahead of print.
Thomas Santo Jr 1, Brodie Clark 1, Matt Hickman 2, Jason Grebely 3, Gabrielle Campbell 1 4, Luis Sordo 5 6, Aileen Chen 1 7, Lucy Thi Tran 1, Chrianna Bharat 1, Prianka Padmanathan 2, Grainne Cousins 8, Julie Dupouy 9 10, Erin Kelty 11, Roberto Muga 12, Bohdan Nosyk 13 14, Jeong Min 13, Raimondo Pavarin 15 16, Michael Farrell 1, Louisa Degenhardt 1
|
|
| |
|
|
| |
|
|
| |
| 11. | "It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C |
| |
Int J Drug Policy. 2021 May 28;97:103280. doi: 10.1016/j.drugpo.2021.103280.Online ahead of print.
Shelley Walker 1, Jack Wallace 2, Ned Latham 2, Freya Saich 2, Alisa Pedrana 3, Margaret Hellard 4, Carla Treloar 5, Tafireyi Marukutira 2, Peter Higgs 6, Joseph Doyle 7, Mark Stoové 3
|
|
| |
| 12. | Effectiveness of the HCV blood screening strategy through eighteen years of surveillance of HCV infection in blood donors in France |
| |
Blood Transfus. 2021 May 12. doi: 10.2450/2021.0032-21. Online ahead of print.
Pierre Cappy 1, Laure Boizeau 1, Daniel Candotti 1, Rémi Caparros 1, Quentin Lucas 1, Eliane Garrabe 2, Christophe Martinaud 2, Sophie Le Cam 3, Pierre Gallian 3 4, Pascal Morel 3 5, Josiane Pillonel 6, Syria Laperche 1
|
|
| |
| 13. | Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019 |
| |
Infez Med. 2021 Jun 1;29(2):242-251.
Barbara Rossetti 1, Lorenzo Paglicci 2, Velia C Di Maio 3, Chiara Cassol 2, Silvia Barbaliscia 3, Stefania Paolucci 4, Bianca Bruzzone 5, Nicola Coppola 6, Francesca Montagnani 2, Valeria Micheli 7, Laura Monno 8, Giacomo Zanelli 2, Teresa Santantonio 9, Nunzia Cuomo 10, Cinzia Caudai 11, Maurizio Zazzi 12, Francesca Ceccherini-Silberstein 3, C On Behalf Of The Hcv Virology Italian Resistance Network Vironet
|
|
| |
| 14. | Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV) |
| |
PLoS Med. 2021 Jun 1;18(6):e1003653. doi: 10.1371/journal.pmed.1003653.eCollection 2021 Jun.
Lars T Fadnes 1 2, Christer Frode Aas 1 2, Jørn Henrik Vold 1 2, Rafael Alexander Leiva 3, Christian Ohldieck 1, Fatemeh Chalabianloo 1 2, Svetlana Skurtveit 4 5, Ole Jørgen Lygren 1 6, Olav Dalgård 7 8, Peter Vickerman 9, Håvard Midgard 7 10, Else-Marie Løberg 1 11 12, Kjell Arne Johansson 1 2, INTRO-HCV Study Group
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 18. | Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes |
| |
Nutr Metab Cardiovasc Dis. 2021 May 1;S0939-4753(21)00186-1.doi: 10.1016/j.numecd.2021.04.016. Online ahead of print.
Ferdinando Carlo Sasso 1, Pia Clara Pafundi 2, Alfredo Caturano 2, Raffaele Galiero 2, Erica Vetrano 2, Riccardo Nevola 2, Salvatore Petta 3, Anna Ludovica Fracanzani 4, Carmine Coppola 5, Vito Di Marco 3, Antonio Solano 6, Rosa Lombardi 4, Mauro Giordano 2, Antonio Craxi 3, Alessandro Perrella 7, Celestino Sardu 2, Raffaele Marfella 2, Teresa Salvatore 8, Luigi Elio Adinolfi 2, Luca Rinaldi 9
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 25. | Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts |
| |
Adv Ther. 2021 Jun;38(6):3409-3426. doi: 10.1007/s12325-021-01753-3. Epub 2021 May 22.
Xavier Forns 1, Jordan J Feld 2, Douglas E Dylla 3, Stanislas Pol 4, Kazuaki Chayama 5, Jinlin Hou 6, Jeong Heo 7, Pietro Lampertico 8 9, Ashley Brown 10, Mark Bondin 3, Fernando Tatsch 3, Margaret Burroughs 3, John Marcinak 3, Zhenzhen Zhang 3, Amanda Emmett 3, Stuart C Gordon 11, Ira M Jacobson 12
|
|
| |
|
|
| |
|
|
| |
| 28. | Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection |
| |
J Hepatol. 2021 May 20;S0168-8278(21)00336-6. doi: 10.1016/j.jhep.2021.04.056.Online ahead of print.
Gail V Matthews 1, Sanjay Bhagani 2, Marc Van der Valk 3, Juergen Rockstroh 4, Jordan J Feld 5, Andri Rauch 6, Christine Thurnheer 6, Julie Bruneau 7, Arthur Kim 8, Margaret Hellard 9, David Shaw 10, Ed Gane 11, Mark Nelson 12, Patrick Ingiliz 13, Tanya L Applegate 14, Jason Grebely 14, Phillipa Marks 14, Marianne Martinello 14, Kathy Petoumenos 14, Gregory J Dore 15, REACT study group; Protocol Steering Committee; Marc van der Valk 16, Margaret Hellard 17, Ed Gane 11, Andri Rauch 18, Julie Bruneau 7, Arthur Kim 19, Sanjay Bhagani 20, Greg Dore 21, Pip Marks 22, Gail Matthews 22, Jason Grebely 22, Kathy Petoumenos 22, Marianne Martinello 22, Tanya Applegate 22, Jordan Feld 23, Jürgen Rockstroh 4, Coordinating Centre; Site Principal Investigators
Collaborators
- Gail Matthews 24, Pip Marks 24, Sophia Amjad 24, Elise Tu 24, Kathy Petoumenos 24, Mahshid Tamaddoni 24, Marc van der Valk 16, Margaret Hellard 17, Ed Gane 11, Maria Christine Thurnheer 18, Yvonne Gilleece 25, Julie Bruneau 7, Mark Nelson 26, Chris Fraser 27, Alberto Moriggia 28, Thomas Lutz 29, Juhi Moon 30, Phillip Read 31, Arthur Y Kim 19, Andrew Ustianowski 32, Christiane Cordes 33, David Shaw 10, Sanjay Bhagani 20, Joe Sasadeusz 34, Mark Hull 35, Greg Dore 21, Jordan Feld 23, Jürgen Rockstroh 4, Dominique Braun 36, Patrick Ingiliz 13
|
|
| |
| 29. | Linkage of resistance-associated substitutions in GT1 sofosbuvir+NS5A inhibitor failures treated with glecaprevir/pibrentasvir |
| |
J Hepatol. 2021 May 20;S0168-8278(21)00339-1. doi: 10.1016/j.jhep.2021.04.057.Online ahead of print.
Gary P Wang 1, Gretja L Schnell 2, Jens J Kort 3, Gurjit S Sidhu 4, Layla Schuster 4, Rakesh L Tripathi 2, Lois Larsen 2, Larry C Michael 5, Ken Bergquist 5, Ashley Magee 5, Chandni B Patel 4, Joan A Whitlock 4, Ryan Tamashiro 4, Joy A Peter 6, Michael W Fried 7, David R Nelson 8
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 33. | Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy |
| |
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549. Online ahead of print.
David A Smith 1 2, Daniel Bradshaw 3, Jean Mbisa 3, Carmen F Manso 3, David Bibby 3, Josh Singer 4, Emma Thomson 4, Ana Filipe 4, Elihu Aranday-Cortes 4, M Azim Ansari 1, Anthony Brown 1, Emma Hudson 1, Jennifer Benselin 5, Brendan Healy 6, Phil Troke 7, John McLauchlan 4, Eleanor Barnes 1 2, William L Irving 5
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 37. | Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease |
| |
Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.
Monica Pons 1, Salvador Augustin, Bernhard Scheiner, Maeva Guillaume, Matteo Rosselli, Susana G Rodrigues, Horia Stefanescu, Mang M Ma, Mattias Mandorfer, Mayka Mergeay-Fabre, Bogdan Procopet, Philipp Schwabl, Arnulf Ferlitsch, Georg Semmler, Annalisa Berzigotti, Emmanuel Tsochatzis, Christophe Bureau, Thomas Reiberger, Jaime Bosch, Juan G Abraldes, Joan Genescà
|
|
| |
| 38. | Characteristics and Donation Outcomes of Potential Organ Donors Perceived to be at Increased Risk for Blood Borne Virus Transmission: an Australian Cohort Study 2010-2018 |
| |
Transplantation. 2021 Feb 22. doi: 10.1097/TP.0000000000003715. Online ahead of print.
Karen M J Waller 1, Nicole L De La Mata, Brenda M Rosales, James A Hedley, Patrick J Kelly, Imogen K Thomson, Michael J O'Leary, Elena Cavazzoni, Vidiya Ramachandran, William D Rawlinson, Kate R Wyburn, Angela C Webster
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 42. | Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease |
| |
Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.
Monica Pons 1, Salvador Augustin, Bernhard Scheiner, Maeva Guillaume, Matteo Rosselli, Susana G Rodrigues, Horia Stefanescu, Mang M Ma, Mattias Mandorfer, Mayka Mergeay-Fabre, Bogdan Procopet, Philipp Schwabl, Arnulf Ferlitsch, Georg Semmler, Annalisa Berzigotti, Emmanuel Tsochatzis, Christophe Bureau, Thomas Reiberger, Jaime Bosch, Juan G Abraldes, Joan Genescà
|
|
| |
| 43. | Characteristics and Donation Outcomes of Potential Organ Donors Perceived to be at Increased Risk for Blood Borne Virus Transmission: an Australian Cohort Study 2010-2018 |
| |
Transplantation. 2021 Feb 22. doi: 10.1097/TP.0000000000003715. Online ahead of print.
Karen M J Waller 1, Nicole L De La Mata, Brenda M Rosales, James A Hedley, Patrick J Kelly, Imogen K Thomson, Michael J O'Leary, Elena Cavazzoni, Vidiya Ramachandran, William D Rawlinson, Kate R Wyburn, Angela C Webster
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 57. | T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy |
| |
Open Forum Infect Dis. 2021 Feb 18;8(4):ofab079.doi: 10.1093/ofid/ofab079.eCollection 2021 Apr.
Ann W N Auma 1, Carey Shive 1, Sofi Damjanovska 2, Corinne Kowal 2, Daniel E Cohen 3, Debika Bhattacharya 4, Beverly Alston-Smith 5, Melissa Osborne 2, Robert Kalayjian 2, Ashwin Balagopal 6, Mark Sulkowski 6, David Wyles 7, Donald D Anthony 1 2 8
|
|
| |
|
|
| |
|
|
| |
| 60. | Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial |
| |
Lancet Gastroenterol Hepatol. 2021 Apr 15;S2468-1253(21)00031-5.doi: 10.1016/S2468-1253(21)00031-5. Online ahead of print.
Isabelle Andrieux-Meyer 1, Soek-Siam Tan 2, Sombat Thanprasertsuk 3, Nicolas Salvadori 4, Caroline Menétrey 5, François Simon 5, Tim R Cressey 6, Hajjah Rosaida Hj Mohd Said 7, Muhammad Radzi Abu Hassan 8, Haniza Omar 2, Hoi-Poh Tee 9, Wah Kheong Chan 10, Suresh Kumar 11, Satawat Thongsawat 12, Kanawee Thetket 13, Anchalee Avihingsanon 14, Suparat Khemnark 15, Sabine Yerly 16, Nicole Ngo-Giang-Huong 17, Sasikala Siva 18, Alistair Swanson 5, Vishal Goyal 19, Francois Bompart 5, Bernard Pécoul 5, Shahnaz Murad 20
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 64. | Hepatitis C Virus Testing Among Men With Human Immunodeficiency Virus Who Have Sex With Men: Temporal Trends and Racial/Ethnic Disparities |
| |
-
Open Forum Infect Dis. 2021 Apr 17;8(4):ofaa645. doi: 10.1093/ofid/ofaa645.eCollection 2021 Apr.
Jun Li 1, Carl Armon 2, Frank J Palella 3, Ellen Tedaldi 4, Richard M Novak 5, Jack Fuhrer 6, Gina Simoncini 4, Kimberly Carlson 2, Kate Buchacz 1, HIV Outpatient Study (HOPS) Investigators
Collaborators
- HIV Outpatient Study (HOPS) Investigators:
-
Jun Li, Kate Buchacz, Marcus D Durham, Cheryl Akridge, Stacey Purinton, Nabil Rayeed, Selom Agbobil-Nuwoaty, Kalliope Chagaris, Kimberly Carlson, Carl Armon, Linda Battalora, Jonathan Mahnken, Frank J Palella, Saira Jahangir, Conor Daniel Flaherty, Patricia Bustamante, John Hammer, Kenneth S Greenberg, Barbara Widick, Rosa Franklin, Douglas J Ward, Troy Thomas, Cheryl Stewart, Jack Fuhrer, Linda Ording-Bauer, Rita Kelly, Jane Esteves, Ellen M Tedaldi, Ramona A Christian, Faye Ruley, Dania Beadle, Princess Davenport, Richard M Novak, Andrea Wendrow, Stockton Mayer, Mia Scott, Billie Thomas, Loraine Van Slyke, Cynthia Mayer, Terry Beitler, Karen Maroney, Denise Franklin
|
|
| |
|
|
| |
| 66. | Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C) |
| |
Harm Reduct J. 2021 Apr 26;18(1):46. doi: 10.1186/s12954-021-00494-4.
Jake Rance 1, Lise Lafferty 2, Carla Treloar 2, SToP-C Study Group
Collaborators
Stuart Loveday, Gregory Dore, Andrew Lloyd, Jason Grebely, Tony Butler, Natasha Martin, Georgina Chambers, Carla Treloar, Marianne Byrne, Roy Donnelly, Colette McGrath, Julia Bowman, Lee Trevethan, Luke Grant, Terry Murrell, Nicky Bath, Mary Harrod, Alison Churchill, Kate Pinnock, Sallie Cairnduff
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 76. | High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California |
| |
PLoS One. 2021 Mar 30;16(3):e0249219. doi: 10.1371/journal.pone.0249219. eCollection 2021.
Christopher J Hernandez 1, Dillon Trujillo 1, Sofia Sicro 1, Joaquin Meza 1, Mackie Bella 1, Emperatriz Daza 1, Francisco Torres 1, Willi McFarland 1 2, Caitlin M Turner 1 2, Erin C Wilson 1 2
|
|
| |
|
|
| |
| 78. | Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study |
| |
Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841. Online ahead of print.
Maureen M Jonas 1, Susan Rhee 2, Deirdre A Kelly 3, Antonio Del Valle-Segarra 4, Cornelia Feiterna-Sperling 5, Susan Gilmour 6, Regino P Gonzalez-Peralta 7, Loreto Hierro 8, Daniel H Leung 9, Simon C Ling 10, Yuri Lobzin 11, Steven Lobritto 12, Tatsuki Mizuochi 13, Michael R Narkewicz 14, Vishakha Sabharwal 15, Jessica Wen 16, Hoi Kei Lon 2, John Marcinak 2, Andrew Topp 2, Rakesh Tripathi 2, Etienne Sokal 17
|
|
| |
|
|
| |
|
|
| |
| 81. | Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era |
| |
Open Forum Infect Dis. 2021 Feb 24;8(3):ofab076. doi: 10.1093/ofid/ofab076.eCollection 2021 Mar.
Shannon Wood 1 2 3 4, Seung Hyun Won 3 5, Hsing-Chuan Hsieh 3 5, Tahaniyat Lalani 3 5 6, Karl Kronmann 3 6, Ryan C Maves 3 7, Gregory Utz 3 7, Christina Schofield 3 4, Rhonda E Colombo 3 5 4, Jason F Okulicz 3 8, Jason Blaylock 2 3, Brian K Agan 3 5, Anuradha Ganesan 2 3 5
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 89. | Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/HCV co-infected women |
| |
AIDS. 2021 Mar 11. doi: 10.1097/QAD.0000000000002869. Online ahead of print.
Audrey L French 1, Dara Grennan, Elizabeth Daubert, Eric C Seaberg, Marion Peters, Michael Augenbraun, Margaret Fischl, Seble Kassaye, Ricardo Franco, Mark Kuniholm, Adaora A Adimora, Kimberly Workowski, Kathleen M Weber
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 93. | Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry |
| |
Clin Infect Dis. 2021 Mar 2;ciaa1510. doi: 10.1093/cid/ciaa1510. Online ahead of print.
Fernanda Q Onofrio 1, Curtis Cooper 2, Sergio M Borgia 3, Marie-Louise Vachon 4, Alnoor Ramji 5, Leslie B Lilly 6, Alexander Wong 7, Joshua Booth 1, Izza Sattar 1, Heidy Morales 1, Samuel Lee 8, Brian Conway 9, Jordan J Feld 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 97. | HCV virology and diagnosis |
| |
Clin Res Hepatol Gastroenterol. 2021 Feb 23;45(3):101626.doi: 10.1016/j.clinre.2021.101626. Online ahead of print.
Steven Roger 1, Alexandra Ducancelle 1, Hélène Le Guillou-Guillemette 1, Catherine Gaudy 2, Françoise Lunel 3
|
|
| |
| 98. | Willingness to Participate in Research among Black Patients with Liver Disease: A National Cross-Sectional Study |
| |
J Viral Hepat. 2021 Mar 4. doi: 10.1111/jvh.13493. Online ahead of print.
F Hunter McGuire 1 2, Kat André 2 3, Minyone L Bradsher 2, Dawn Harrison 4, Richard K Sterling 5, K Rajender Reddy 6, Marina Serper 6, Carol E Golin 1 7, Nancy Reau 8, Joseph K Lim 9, David R Nelson 10, Souvik Sarkar 11, Donna M Evon 2 4
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 103. | Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment |
| |
J Addict Med. 2021 Feb 5. doi: 10.1097/ADM.0000000000000807. Online ahead of print.
Kristi Hill 1, Laura Nussdorf, Julia D Mount, Rachel Silk, Chloe Gross, David Sternberg, Phyllis Bijole, Miriam Jones, Randy Kier, Dana Mccullough, Poonam Mathur, Shyam Kottilil, Henry Masur, Sarah Kattakuzhy, Elana S Rosenthal
|
|
| |
| 104. | The persistence of underreporting of hepatitis C as an underlying or contributing cause of death, 2011-2017 |
| |
Clin Infect Dis. 2021 Feb 9;ciab108. doi: 10.1093/cid/ciab108. Online ahead of print.
Philip R Spradling 1, Yuna Zhong 1, Anne C Moorman 1, Loralee B Rupp 2, Mei Lu 2, Eyasu H Teshale 1, Mark A Schmidt 3, Yihe G Daida 4, Joseph A Boscarino 5, Stuart C Gordon 2 6
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 111. | Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study |
| |
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):169-184. doi: 10.1016/S2468-1253(20)30359-9.Epub 2021 Jan 28.
Ellen Dugan 1, Sarah Blach 1, Mia Biondi 2, Zongzhen Cai 1, Mindi DePaola 1, Chris Estes 1, Jordan Feld 3, Ivane Gamkrelidze 1, Shyamasundaran Kottilil 4, Siya Ma 1, Poonam Mathur 1, Shauna Montoya 1, Devin Razavi-Shearer 1, Kathryn Razavi-Shearer 1, Sarah Robbins-Scott 1, Jonathan Schmelzer 1, Homie Razavi 5
|
|
| |
| 112. | Outcomes of Hepatitis C Virus Seropositive Donors to Hepatitis C Virus Seronegative Liver Recipients: A Large Single Center Analysis |
| |
Ann Hepatol. 2021 Jan 27;100318. doi: 10.1016/j.aohep.2021.100318. Online ahead of print.
Lindsay A Sobotka 1, Khalid Mumtaz 1, Michael R Wellner 1, Sean G Kelly 1, Lanla F Conteh 1, A James Hanje 1, Austin Schenk 2, Ashraf El-Hinnawi 2, Sylvester Black 2, Kenneth Washburn 2, Todd Pesavento 3, Reem Daloul 3, Anthony J Michaels 4
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 121. | Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response |
| |
Clin Gastroenterol Hepatol. 2021 Jan 22;S1542-3565(21)00076-8.doi:10.1016/j.cgh.2021.01.026. Online ahead of print.
Zobair M Younossi 1, Andrei Racila 2, Andrew Muir 3, Marc Bourliere 4, Alessandra Mangia 5, Rafael Esteban 6, Stefan Zeuzem 7, Massimo Colombo 8, Michael Manns 9, George V Papatheodoridis 10, Maria Buti 6, Anand Chokkalingam 11, Anuj Gaggar 11, Fatema Nader 12, Issah Younossi 12, Linda Henry 12, Maria Stepanova 12
|
|
| |
|
|
| |
| 123. | Hepatitis C Virus Transmission Clusters in Public Health and Correctional Settings, Wisconsin, USA, 2016-2017 1 |
| |
Emerg Infect Dis. 2021 Feb;27(2):480-489. doi: 10.3201/eid2702.202957.
Karli R Hochstatter, Damien C Tully, Karen A Power, Ruth Koepke, Wajiha Z Akhtar, Audrey F Prieve, Thomas Whyte, David J Bean, David W Seal, Todd M Allen, Ryan P Westergaard
|
|
| |
|
|
| |
| 125. | Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis |
| |
JGH Open. 2020 Dec 10;5(1):133-142. doi: 10.1002/jgh3.12462. eCollection 2021 Jan.
Steven M McPhail 1 2, Samath Amarasena 3, Katherine A Stuart 4, Kelly Hayward 5, Rohit Gupta 6, David Brain 1 2, Gunter Hartel 7, Tony Rahman 6, Paul J Clark 8, Christina M Bernardes 6, Richard Skoien 3, Benjamin Mckillen 3, Andrew Lee 8, Leshni Pillay 9, Lei Lin 6, Myat Myat Khaing 6, Leigh Horsfall 4 5, Elizabeth E Powell 4 5, Patricia C Valery 7
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 129. | Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives |
| |
J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474. Online ahead of print.
Julius M Wilder 1 2, Donna M Evon 3, Rae Jean Proeschold-Bell 4 5, Jia Yao 4 5, Malik Muhammed Sohail 4, Donna Niedzwiecki 6, Christina Makarushka 4 5, Terra Hodge 1, Andrew J Muir 1 2
|
|
| |
| 130. | HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men |
| |
Transfusion. 2021 Jan 18. doi: 10.1111/trf.16250. Online ahead of print.
Whitney R Steele 1, Roger Y Dodd 1, Edward P Notari 1, James Haynes 1, Steven A Anderson 2, Alan E Williams 2, Rita Reik 3, Debra Kessler 4, Brian Custer 5, Susan L Stramer 1, Transfusion-Transmissible Infections Monitoring System (TTIMS)
|
|
| |
|
|
| |
|
|
| |
| 133. | Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study |
| |
Open Forum Infect Dis. 2020 Nov 19;8(1):ofaa564. doi: 10.1093/ofid/ofaa564.eCollection 2021 Jan.
Kristina M Brooks 1, Jose R Castillo-Mancilla 2, Mary Morrow 3, Samantha MaWhinney 3, Sarah E Rowan 2 4, David Wyles 2 4, Joshua Blum 4, Ryan Huntley 1, Lana M Salah 1, Arya Tehrani 1, Lane R Bushman 1, Peter L Anderson 1, Jennifer J Kiser 1
|
|
| |
|
|
| |
|
|
| |
| 136. | Patient-Reported Outcomes 12 Months After Hepatitis C Treatment with Direct-Acting Antivirals: Results from the PROP UP Study |
| |
Liver Int. 2021 Jan 2. doi: 10.1111/liv.14781. Online ahead of print.
Marina Serper 1, Donna M Evon 2, Jipcy Amador 3, Paul W Stewart 3, Souvik Sarkar 4, Anna S Lok 5, Richard K Sterling 6, Bryce B Reeve 7, Carol E Golin 8, K Rajender Reddy 1, Joseph K Lim 9, Nancy Reau 10, David R Nelson 11, Adrian M Di Bisceglie 12, Michael W Fried 2
|
|
| |
|
|
| |
|
|
| |
| 139. | Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond |
| |
Chem Rev. 2021 Jan 7. doi: 10.1021/acs.chemrev.0c00648. Online ahead of print.
Ashley N Matthew 1, Florian Leidner 1, Gordon J Lockbaum 1, Mina Henes 1, Jacqueto Zephyr 1, Shurong Hou 1, Desaboini Nageswara Rao 1, Jennifer Timm 1, Linah N Rusere 1, Debra A Ragland 1, Janet L Paulsen 1, Kristina Prachanronarong 1, Djade I Soumana 1, Ellen A Nalivaika 1, Nese Kurt Yilmaz 1, Akbar Ali 1, Celia A Schiffer 1
|
|
| |
| 140. | HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status |
| |
Clin Infect Dis. 2020 Dec 21;ciaa1869.doi: 10.1093/cid/ciaa1869. Online ahead of print.
Risha Irvin 1, Theresa Gamble 2, Jowanna Malone 1, Zhe Wang 3, Ethan Wilson 3, James P Hughes 4, Jason Farley 1, Kenneth H Mayer 5, Carlos Del Rio 6, D Scott Batey 7, Vanessa Cummings 1, Robert H Remien 8, Chris Beyrer 1, Chloe L Thio 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 147. | Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy |
| |
J Hepatol. 2020 Nov 18;S0168-8278(20)33770-3. doi: 10.1016/j.jhep.2020.11.017.Online ahead of print.
Julia Dietz 1, Velia Chiara Di Maio 2, Adolfo de Salazar 3, Dolores Merino 4, Johannes Vermehren 1, Stefania Paolucci 5, Andreas E Kremer 6, Magdalena Lara 7, Maria Rodriguez Pardo 8, Heinz Zoller 9, Elisabetta Degasperi 10, Kai-Henrik Peiffer 1, Laura Sighinolfi 11, Francisco Téllez 12, Christiana Graf 1, Valeria Ghisetti 13, Jonas Schreiber 14, Elisa Fernández-Fuertes 15, Lucio Boglione 16, Leopoldo Muñoz-Medina 17, Rudolf Stauber 18, William Gennari 19, Blanca Figueruela 20, Jesús Santos 21, Pietro Lampertico 10, Stefan Zeuzem 1, Francesca Ceccherini-Silberstein 2, Federico García 3, Christoph Sarrazin 22
|
|
| |
|
|
| |
|
|
| |
| 150. | Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs |
| |
Drug Alcohol Rev. 2020 Nov 8. doi: 10.1111/dar.13198. Online ahead of print.
Vivian D Hope 1, James McVeigh 2, Emma Begley 1, Rachel Glass 3, Claire Edmundson 3, Ellen Heinsbroek 3, Joseph Kean 4, John Campbell 5, Mark Whitfield 1, Gareth Morgan 6, Dean Acreman 7, Josie Smith 7
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 154. | Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C Treated Liver Transplant Recipients with Residual Fibrosis or Cirrhosis |
| |
Liver Transpl. 2020 Nov 8. doi: 10.1002/lt.25934. Online ahead of print.
Ethan W Weinberg 1, Michael P Curry 2, Catherine T Frenette 3, Fredric G Regenstein 4, Eugene R Schiff 5, Zachary D Goodman 6, James Mac Robinson 7, Jean L Chan 7, Joanne C Imperial 7, K Rajender Reddy 1
|
|
| |
| 155. | Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV |
| |
J Infect Dis. 2020 Nov 3;jiaa686. doi: 10.1093/infdis/jiaa686. Online ahead of print.
Danielle F Haley 1, Andrew Edmonds 2, Catalina Ramirez 3, Audrey L French 4, Phyllis Tien 5, Chloe L Thio 6, Mallory D Witt 7, Eric C Seaberg 8, Michael W Plankey 9, Mardge H Cohen 10, Adaora A Adimora 11
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 159. | A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C |
| |
BMC Infect Dis. 2020 Oct 29;20(1):802. doi: 10.1186/s12879-020-05531-4.
Jessica Ramsay 1, Julie Marsh 1, Alisa Pedrana 2 3, Nada Andric 4, Richard Norman 5, Wendy Cheng 6 7 8, Steve Webb 3 9, Nikolajs Zeps 10, Matthew Bellgard 11, Todd Graves 12, Margaret Hellard 2 3 13 14 15, Tom Snelling 16 17 18 19 20
|
|
| |
| 160. | Early Outcomes of Multivisceral Transplant using Hepatitis C Positive Donors |
| |
Ann Thorac Surg. 2020 Oct 26;S0003-4975(20)31736-7. doi: 10.1016/j.athoracsur.2020.08.044.Online ahead of print.
William G McMaster Jr 1, Zakiur M Rahaman 2, Maren E Shipe 3, Eric N Quintana 4, Emily M Sandhaus 5, Sarah S Smith 6, Jerod E Crockett 7, Rachel C Forbes 8, Kelly H Schlendorf 9, Ashish S Shah 10
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 169. | Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV |
| |
mSystems. 2020 Oct 13;5(5):e00528-20. doi: 10.1128/mSystems.00528-20.
Bryn C Taylor # 1, Kelly C Weldon # 2 3, Ronald J Ellis 4 5, Donald Franklin 6, Daniel McDonald 7, Gregory Humphrey 7, MacKenzie Bryant 7, Julia Toronczak 7, Tara Schwartz 7, Jennifer Iudicello 6, Robert Heaton 6, Igor Grant 6, Sara Gianella 8
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 181. | Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection |
| |
J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408. Online ahead of print.
Philip J Johnson 1, Sarah Berhane 1, Alex J Walker 2, Fiona H Gordon 3, Steven D Ryder 4 5, Stuart McPherson 6, Aravamuthan Sreedharan 7, Andrew A Ustianowski 8, Kosh Agarwal 9, David Mutimer 10, Takeshi Kumada 11, Hidenori Toyoda 12, William L Irving 5, HCV Research UK
|
|
| |
| 182. | Depression in Individuals Coinfected with HIV and HCV Is Associated with Systematic Differences in the Gut Microbiome and Metabolome |
| |
mSystems. 2020 Sep 29;5(5):e00465-20. doi: 10.1128/mSystems.00465-20.
Bryn C Taylor 1, Kelly C Weldon 2 3, Ronald J Ellis 4 5, Donald Franklin 6, Tobin Groth 7, Emily C Gentry 2, Anupriya Tripathi 2 7 8, Daniel McDonald 8, Gregory Humphrey 8, MacKenzie Bryant 8, Julia Toronczak 8, Tara Schwartz 8, Michelli F Oliveira 9, Robert Heaton 6, Igor Grant 6, Sara Gianella 10, Scott Letendre 9 11, Austin Swafford 3, Pieter C Dorrestein 2 3 8, Rob Knight 12 8 13 14
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 191. | Cholesterol sensing by CD81 is important for hepatitis C virus entry |
| |
J Biol Chem. 2020 Sep 8;jbc.RA120.014761. doi: 10.1074/jbc.RA120.014761.Online ahead of print.
Machaela Palor 1, Lenka Stejskal 1, Piya Mandal 1, Annasara Lenman 2, Maria Pia Alberione 3, Jared Kirui 4, Rebecca Moeller 4, Stefan Ebner 5, Felix Meissner 5, Gisa Gerold 6, Adrian J Shepherd 7, Joe Grove 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 200. | Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or |
| |
J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13393. Online ahead of print.
David Stephen Prince 1 2, Joseph Louis Pipicella 1 3, Melissa Fraser 1, Frank Alvaro 1 4, Michael Maley 1 2 4, Hong Foo 1 4 5, Paul MacConachie Middleton 1 2 3 6 7, Scott Anthony Davison 1 2, Greg John Dore 8, Geoff William McCaughan 7 9, Miriam Tania Levy 1 2 3
|
|
| |
| 201. | Hepatitis C Virus |
| |
Ann Intern Med. 2020 Sep 1;173(5):ITC33-ITC48. doi: 10.7326/AITC202009010.
|
|
| |
|
|
| |
|
|
| |
| 204. | Hepatic benefits of HCV cure |
| |
J Hepatol. 2020 Aug 7;S0168-8278(20)30530-4. doi: 10.1016/j.jhep.2020.08.006.Online ahead of print.
Vincenza Calvaruso 1, Antonio Craxì 2
|
|
| |
| 205. | Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper |
| |
J Pediatr Gastroenterol Nutr. 2020 Sep;71(3):407-417. doi: 10.1097/MPG.0000000000002814.
Daniel H Leung 1, James E Squires 2, Ravi Jhaveri 3, Nanda Kerkar 4, Chuan-Hao Lin 5, Parvathi Mohan 6, Karen F Murray 7, Regino P Gonzalez-Peralta 8, Eve A Roberts 9, Shikha S Sundaram 10
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 217. | Global hepatitis C elimination: an investment framework |
| |
Lancet Gastroenterol Hepatoldoi: 10.1016/S2468-1253(20)30010-8. Online ahead of print.
Alisa Pedrana 1, Jessica Howell 2, Nick Scott 3, Sophia Schroeder 3, Christian Kuschel 4, Jeffrey V Lazarus 5, Rifat Atun 6, Ricardo Baptista-Leite 7, Ellen 't Hoen 8, Sharon J Hutchinson 9, Lisa Aufegger 10, Raquel Peck 11, Annette H Sohn 12, Tracy Swan 13, Mark Thursz 14, Olufunmilayo Lesi 15, Manik Sharma 16, John Thwaites 17, David P Wilson 3, Margaret Hellard 18
|
|
| |
| 218. | Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020 MMWR |
| |
Recomm Rep. 2020 Jul 24;69(6):1-8. doi: 10.15585/mmwr.rr6906a1.
MMWR Recomm Rep. 2020 Jul 24;69(6):1-8. doi: 10.15585/mmwr.rr6906a1.
Anne C Moorman, Marie A de Perio, Ronald Goldschmidt, Carolyn Chu, David Kuhar, David K Henderson, Susanna Naggie, Saleem Kamili, Philip R Spradling, Stuart C Gordon, Mark B Russi, Eyasu H Teshale
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 224. | Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience |
| |
Transplant Proc. 2020 Jul 4;S0041-1345(20)32581-1. doi:10.1016/j.transproceed.2020.06.005.Online ahead of print.
Eloi Chevallier 1, Matthias Büchler 2, Sophie Caillard 3, Nicolas Bouvier 4, Charlotte Colosio 5, Joseph Rivalan 6, Johnny Sayegh 7, Dominique Bertrand 8, Yannick Le Meur 9, Antoine Thierry 10, Cyril Garrouste 11, Jean-Philippe Rerolle 12, Lionel Rostaing 13, Philippe Gatault 2
|
|
| |
|
|
| |
| 226. | Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions |
| |
Liver Int. 2020 Jul 8. doi: 10.1111/liv.14591. Online ahead of print.
Julia Dietz 1, Johannes Vermehren 1, Katrin Matschenz 2, Peter Buggisch 2, Hartwig Klinker 3, Julian Schulze Zur Wiesch 4, Holger Hinrichsen 5, Kai-Henrik Peiffer 1, Christiana Graf 1, Thomas Discher 6, Janina Trauth 6, Jörn M Schattenberg 7, Felix Piecha 4, Stefan Mauss 8, Claus Niederau 9, Tobias Müller 10, Christoph Neumann-Haefelin 11, Christoph P Berg 12, Stefan Zeuzem 1, Christoph Sarrazin 1 13, European HCV Resistance Study Group
|
|
| |
| 227. | Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014 : A Study of Health Care Encounter Data |
| |
Public Health Rep. Jul/Aug 2020;135(4):461-471. doi: 10.1177/0033354920937284.Epub 2020 Jul 7.
Mary E Evans 1 2 3, Marissa Person 4, Brigg Reilley 5, Jessica Leston 5, Richard Haverkate 6, Jeffrey T McCollum 6, Andria Apostolou 6 7, Michele K Bohm 1, Michelle Van Handel 8, Danae Bixler 9, Andrew J Mitsch 2, Dana L Haberling 4, Sarah M Hatcher 3 5, Thomas Weiser 10, Kim Elmore 2, Eyasu H Teshale 9, Paul J Weidle 2, Philip J Peters 2, Kate Buchacz 2
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 231. | Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection |
| |
Clin Gastroenterol Hepatol. 2020 Jul 1;S1542-3565(20)30907-1. doi: 10.1016/j.cgh.2020.06.044.Online ahead of print.
Eli Zuckerman 1, Julio A Gutierrez 2, Douglas E Dylla 3, Victor de Ledinghen 4, Andrew J Muir 5, Michael Gschwantler 6, Massimo Puoti 7, Florin Caruntu 8, Jihad Slim 9, Frederik Nevens 10, Samuel Sigal 11, Stanley Cohen 12, Linda M Fredrick 3, Ana Gabriela Pires Dos Santos 3, Lino Rodrigues Jr 3, John F Dillon 13
|
|
| |
| 232. | Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals |
| |
Int J Antimicrob Agents. 2020 Jun 26;106067. doi: 10.1016/j.ijantimicag.2020.106067.Online ahead of print.
M Pisaturo 1, M Starace 1, C Minichini 1, S De Pascalis 2, L Occhiello 1, A Di Fraia 1, V Messina 3, V Sangiovanni 4, E Claar 5, N Coppola 6, CampC Network
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 236. | The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services |
| |
PLoS One. 2020 Jun 30;15(6):e0235445.doi: 10.1371/journal.pone.0235445. eCollection 2020.
Michael W Traeger 1 2, Alisa E Pedrana 1 2, Daniela K van Santen 1 2, Joseph S Doyle 1 3, Jessica Howell 1 4, Alexander J Thompson 4, Carol El-Hayek 1, Jason Asselin 1, Victoria Polkinghorne 1, Dean Membrey 5, Fran Bramwell 5, Allison Carter 6, Rebecca Guy 6, Mark A Stoové 1 2 7, Margaret E Hellard 1 2 3, EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 240. | Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study |
| |
Lancet Gastroenterol Hepatol. 2020 Jun 9;S2468-1253(19)30417-0.doi: 10.1016/S2468-1253(19)30417-0. Online ahead of print.
Eric Lawitz 1, Charles S Landis 2, Steven L Flamm 3, Maurizio Bonacini 4, Grisell Ortiz-Lasanta 5, Jonathan Huang 6, Jie Zhang 7, Brian J Kirby 7, Shampa De-Oertel 7, Robert H Hyland 7, Anu O Osinusi 7, Diana M Brainard 7, Richard Robson 8, Benedict J Maliakkal 6, Stuart C Gordon 9, Edward J Gane 10
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 244. | Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance |
| |
Hepatol Commun. 2020 Apr 6;4(6):904-915. doi: 10.1002/hep4.1496. eCollection 2020 Jun.
Mark W Douglas 1 2 3, Enoch S E Tay 1 4, Dao Sen Wang 1, Adrian T L Ong 1 2, Caroline Wilson 1, Amy Phu 1, Jen Kok 4, Dominic E Dwyer 3 4, Rowena A Bull 5, Andrew R Lloyd 5, Tanya L Applegate 5, Gregory J Dore 5, Anita Y Howe 6, Richard Harrigan 7, Jacob George 1 3
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 254. | Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a |
| |
Adv Ther. 2020 Jul;37(7):3299-3310. doi: 10.1007/s12325-020-01389-9. Epub 2020 May 25.
Philip Rosenthal 1, Michael R Narkewicz 2, Betty B Yao 3, Christopher D Jolley 4, Steven J Lobritto 5, Jessica Wen 6, Jean P Molleston 7, Evelyn K Hsu 8, Maureen M Jonas 9, Jiuhong Zha 3, Li Liu 3, Daniel H Leung 10
|
|
| |
|
|
| |
|
|
| |
| 257. | Public Health Clinic-Based Hepatitis C Treatment |
| |
Am J Prev Med. 2020 May 16;S0749-3797(20)30146-X. doi:10.1016/j.amepre.2020.03.006.Online ahead of print.
Amanda M Rosecrans 1, Aneesha Cheedalla 2, Sarah T Rives 3, Lisa A Scotti 3, Robert E Harris 3, Adena H Greenbaum 4, Risha R Irvin 2, Boatemaa A Ntiri-Reid 5, Holly T Brown 3, Karen E Alston 3, Jaeson A Smith 4, Kathleen R Page 3, Oluwaseun O Falade-Nwulia 2
|
|
| |
|
|
| |
| 259. | English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed |
| |
Kathryn Drysdale 1 2, Yevedzo Ntuli 1 3, Jonathan Bestwick 4, William Gelson 5, Kosh Agarwal 3, Daniel Forton 6, David Mutimer 7, Ahmed M Elsharkawy 7, Ceri Townley 8, Faizel Mahomed 9, Graham R Foster 1 2
Aliment Pharmacol Ther. 2020 Jul;52(1):168-181. doi: 10.1111/apt.15780. Epub 2020 May 22.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 263. | Resistance-associated Substitutions in Patients With Chronic Hepatitis C Virus Genotype 4 Infection |
| |
J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322. Online ahead of print.
Julia Dietz 1 2, Olga V Kalinina 3 4, Johannes Vermehren 1 2, Kai-Henrik Peiffer 1 2, Katrin Matschenz 5, Peter Buggisch 5, Claus Niederau 6, Jörn M Schattenberg 7, Beat Müllhaupt 8, Sabine Yerly 9, Marc Ringelhan 10, Roland M Schmid 10, Christoph Antoni 11, Tobias Müller 12, Julian Schulze Zur Wiesch 13 14, Felix Piecha 13, Darius Moradpour 15, Katja Deterding 16 17 18, Heiner Wedemeyer 16 17 18, Christophe Moreno 19, Thomas Berg 20, Christoph P Berg 21, Stefan Zeuzem 1 2, Christoph Welsch 1 2, Christoph Sarrazin 1 2 22, European HCV Resistance Study Group
|
|
| |
|
|
| |
| 265. | HCV DAA Therapy in Persons With HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation |
| |
J Infect Dis. 2020 May 15;jiaa254.doi: 10.1093/infdis/jiaa254. Online ahead of print.
Donald D Anthony 1, Mark S Sulkowski 2, Laura M Smeaton 3, Sofi Damjanovska 1, Carey L Shive 1, Corinne M Kowal 1, Daniel E Cohen 4, Debika Bhattacharya 5, Beverly L Alston-Smith 6, Ashwin Balagopal 2, David L Wyles 7
|
|
| |
| 266. | High Prevalence of Hepatitis C Infection Among Adult Patients at Four Urban Emergency Departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017 |
| |
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):569-574 doi: 10.15585/mmwr.mm6919a1.
James W Galbraith, Erik S Anderson, Yu-Hsiang Hsieh, Ricardo A Franco, John P Donnelly, Joel B Rodgers, Elissa M Schechter-Perkins, William W Thompson, Noele P Nelson, Richard E Rothman, Douglas A E White
Free PMC article
|
|
| |
| 267. | Impact of Treatment With Direct Acting Antiviral Drugs on Glycemic Control in Patients With Hepatitis C and Diabetes Mellitus |
| |
Int J Hepatol. 2020 Jan 13;2020:6438753. doi: 10.1155/2020/6438753. eCollection 2020.
Pradeep Kumar Mada 1 2, Matthew E Malus 3, Arvin Parvathaneni 4, Bing Chen 3, Gabriel Castano 5, Sharon Adley 2, Maureen Moore 2, Michinari Hieda 6, Mohammed J Alam 2, Mark Feldman 1, John William King 2
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 273. | Eliciting Patient Views on the Allocation of Limited Healthcare Resources: A Deliberation on Hepatitis C Treatment in the Veterans Health Administration |
| |
BMC Health Serv Res. 2020 May 1;20(1):369. doi: 10.1186/s12913-020-05211-8.
Akbar K Waljee 1 2 3, Kerry A Ryan 4, Chris D Krenz 4, George N Ioannou 5 6, Lauren A Beste 6 7, Monica A Tincopa 8, Sameer D Saini 9 8 10, Grace L Su 9 8, Maria E Arasim 9, Patti T Roman 9, Brahmajee K Nallamothu 9 10 11, Raymond De Vries 4
|
|
| |
|
|
| |
| 275. | Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model |
| |
Open. 2020 May 1;3(5):e204192. doi: 10.1001/jamanetworkopen.2020.4192.
Mawuena Binka 1, Naveed Z Janjua 1 2 3, Jason Grebely 2 4, Chris Estes 5, Dena Schanzer 2, Jisoo A Kwon 4, Naglaa H Shoukry 2 6, Jeffrey C Kwong 2 7, Homie Razavi 5, Jordan J Feld 2 8, Mel Krajden 1 2 3
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 280. | Utilization and Effectiveness of elbasvir/grazoprevir and Adoption of Resistance-Associated Substitutions Testing in Real-World Treatment of Hepatitis C Virus Genotype 1A Infection: Results From the German Hepatitis C-Registry |
| |
Eur J Gastroenterol Hepatol. 2020 May 15. doi: 10.1097/MEG.0000000000001759.Online ahead of print.
Holger Hinrichsen 1, Albrecht Stoehr 2, Markus Cornberg 3, Hartwig Klinker 4, Renate Heyne 5, Christine John 6, Karl-Georg Simon 7, Veronika Guenther 8, Karen Martin 8, Vanessa Witte 8, Stefan Zeuzem 9
|
|
| |
|
|
| |
|
|
| |
| 283. | Hepatitis C Prevalence and Risk Factors in Georgia, 2015: Setting a Baseline for Elimination |
| |
BMC Public Health. 2019 May 10;19(Suppl 3):480. doi: 10.1186/s12889-019-6784-3.
Liesl M Hagan 1, Ana Kasradze 2, Stephanie J Salyer 3, Amiran Gamkrelidze 2, Maia Alkhazashvili 2, Gvantsa Chanturia 2, Nazibrola Chitadze 2, Roena Sukhiashvili 2, Marina Shakhnazarova 2, Steven Russell 3, Curtis Blanton 3, Giorgi Kuchukhidze 2, Davit Baliashvili 2, Susan Hariri 4, Stephen Ko 4 5, Paata Imnadze 2, Jan Drobeniuc 4, Juliette Morgan 3 6, Francisco Averhoff 4
|
|
| |
| 284. | An Evaluation of the Hepatitis C Testing, Care and Treatment Program in the Country of Georgia's Corrections System, December 2013 - April 2015 |
| |
BMC Public Health. 2019 May 10;19(Suppl 3):466. doi: 10.1186/s12889-019-6783-4.
Aaron M Harris 1, Otar Chokoshvili 2, Joshua Biddle 3, Kostantine Turashvili 4, Maia Japaridze 5, Irma Burjanadze 6, Tengiz Tsertsvadze 2, Lali Sharvadze 2, Marine Karchava 2, Archil Talakvadze 7, Ketevan Chakhnashvili 4, Tamta Demurishvili 4, Paata Sabelashvili 8, Monique Foster 9 10, Liesl Hagan 9, Maia Butsashvili 11, Juliette Morgan 5 12, Francisco Averhoff 9
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 292. | Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation |
| |
Kidney Int Rep. 2020 Jan 13;5(4):459-467.doi: 10.1016/j.ekir.2020.01.001. eCollection 2020 Apr.
Meghan E Sise 1, Ian A Strohbehn 2, Donald F Chute 2, Jenna Gustafson 2, Vivianna M Van Deerlin 3, Jennifer R Smith 3, Caren Gentile 3, David Wojciechowski 4, Winfred W Williams 1, Nahel Elias 5, Raymond T Chung 2
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 304. | Simeprevir, Daclatasvir, and Sofosbuvir for Hepatitis C Virus-Infected Patients: Long-term Follow-Up Results From the Open-Label, Phase II IMPACT Study |
| |
Health Sci Rep. 2020 Feb 22;3(2):e145. doi: 10.1002/hsr2.145. eCollection 2020 Jun.
Eric Lawitz 1, Fred Poordad 1, Julio A Gutierrez 2, Maria Beumont 3, Greet Beets 3, Ann Vandevoorde 3, Pieter Van Remoortere 4, Donghan Luo 4, Leen Vijgen 3, Veerle Van Eygen 3, Mohamed Gamil 3
|
|
| |
| 305. | Elbasvir and Grazoprevir for Hepatitis C Virus Genotype 1 Infection in People With Recent Injecting Drug Use (DARLO-C): An Open-Label, Single-Arm, Phase 4, Multicentre Trial |
| |
Health Sci Rep. 2020 Mar 15;3(2):e151. doi: 10.1002/hsr2.151. eCollection 2020 Jun.
Jason Grebely 1, Phillip Read 2, Evan B Cunningham 1, Martin Weltman 3, Gail V Matthews 1 4, Adrian Dunlop 5, Mark Montebello 6, Marianne Martinello 1 4, Rosie Gilliver 2, Philippa Marks 1, Tanya L Applegate 1, Gregory J Dore 1 4, DARLO-C Study Group
|
|
| |
| 306. | Infective Endocarditis Among Persons Aged 18-64 Years With HIV, Hepatitis C Infection, or Opioid Use Disorder - United States, 2007-2017 |
| |
Clin Infect Dis. 2020 Apr 9;ciaa372. doi: 10.1093/cid/ciaa372. Online ahead of print.
Cecillia Y Wong 1, Weiming Zhu 2, Gerard P Aurigemma 1, Nathan Furukawa 2, Eyasu H Teshale 3, Ya-Lin A Huang 2, Philip J Peters 2, Karen W Hoover 2
|
|
| |
|
|
| |
| 308. | Ombitasvir/paritaprevir/ritonavir & Dasabuvir ± Ribavirin Following Protease Inhibitors Failure - A Prospective Multi-Centre Trial |
| |
BMC Infect Dis. 2020 Apr 3;20(1):264. doi: 10.1186/s12879-020-4921-3.
Liat Deutsch 1 2, Inbal Houri 1 2, Ziv Ben-Ari 2 3, Amir Shlomai 2 4, Ella Veitsman 2 3, Oranit Cohen-Ezra 2 3, Assaf Issachar 2 4, Orna Mor 5 6, Yael Gozlan 5, Rafael Bruck 1 2, Yoram Menachem 1 2, Shira Zelber-Sagi 1 7, Helena Katchman 1 2, Oren Shibolet 8 9
|
|
| |
|
|
| |
|
|
| |
| 311. | Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017 |
| |
J Clin Gastroenterol. 2020 Apr 3. doi: 10.1097/MCG.0000000000001344. Online ahead of print.
Philip R Spradling 1, Jian Xing 1, Loralee B Rupp 2, Anne C Moorman 1, Stuart C Gordon 2 3, Mei Lu 2, Eyasu H Teshale 1, Joseph A Boscarino 4, Mark A Schmidt 5, Yihe G Daida 6, Scott D Holmberg 1, Chronic Hepatitis Cohort Study (CHeCS) Investigators
|
|
| |
|
|
| |
| 313. | Antibody Avidity-Based Approach to Estimate Population-Level Incidence of Hepatitis C |
| |
Hepatol. 2020 Mar 30;S0168-8278(20)30190-2. doi: 10.1016/j.jhep.2020.03.028.Online ahead of print.
Denali Boon 1, Veronica Bruce 2, Eshan U Patel 3, Jeffery Quinn 3, Aylur K Srikrishnan 4, Saravanan Shanmugam 4, Syed Iqbal 4, Pachamuthu Balakrishnan 4, Matthew Sievers 3, Gregory D Kirk 3, David L Thomas 3, Thomas C Quinn 5, Andrea L Cox 3, Kimberly A Page 2, Sunil S Solomon 6, Shruti H Mehta 3, Oliver Laeyendecker 5
|
|
| |
|
|
| |
| 315. | Health of Special Immigrant Visa Holders From Iraq and Afghanistan After Arrival Into the United States Using Domestic Medical Examination Data, 2014-2016: A Cross-Sectional Analysis |
| |
PLoS Med. 2020 Mar 31;17(3):e1003083. doi: 10.1371/journal.pmed.1003083.eCollection 2020 Mar.
Gayathri S Kumar 1, Clelia Pezzi 1, Simone Wien 1, Blain Mamo 2, Kevin Scott 3, Colleen Payton 3, Kailey Urban 2, Stephen Hughes 4, Lori Kennedy 5, Nuny Cabanting 6, Jessica Montour 7, Melissa Titus 8, Jenny Aguirre 9, Breanna Kawasaki 5, Rebecca Ford 10, Emily S Jentes 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 319. | The Impact of SVR From Direct-Acting Antiviral- And Interferon-Based Treatments for HCV on Hepatocellular Carcinoma Risk |
| |
J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13295. Online ahead of print.
Naveed Z Janjua 1 2, Stanley Wong 1, Maryam Darvishian 1 2 3, Zahid A Butt 1 2, Amanda Yu 1, Mawuena Binka 1, Maria Alvarez 1, Ryan Woods 3, Eric M Yoshida 4, Alnoor Ramji 4, Jordan Feld 5, Mel Krajden 1 6
|
|
| |
|
|
| |
| 321. | Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Global Federation of International Societies of International Societies of Pediatric Gastroenterology, Hepatology and Nutrition (FISPGHAN) |
| |
J Pediatr Gastroenterol Nutr. 2020 Mar 20.
doi: 10.1097/MPG.0000000000002710.Online ahead of print.
Giuseppe Indolfi 1, Björn Fischler 2, Regino P Gonzalez-Peralta 3, Mirta Ciocca 4, Gilda Porta 5, Mohan Neelam 6, Mohammed El-Guindi 7, Deirdre Kelly 8, Yen-Hsuan Ni 9, Anupan Sibal 10, Daniel H Leung 11, Mei Hwei Chang 12, Hepatitis Expert Team of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN)
|
|
| |
| 322. | Population Impact of Direct-Acting Antiviral Treatment on New Presentations of Hepatitis C-related Decompensated Cirrhosis: A National Record-Linkage Study |
| |
Gut. 2020 Mar 26;gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007. Online ahead of print.
Sharon J Hutchinson 1 2, Heather Valerio 3 2, Scott A McDonald 3 2, Alan Yeung 3 2, Kevin Pollock 3 2, Shanley Smith 3 2, Stephen Barclay 3 4, John F Dillon 5, Raymond Fox 6, Peter Bramley 7, Andrew Fraser 8 9, Nicholas Kennedy 10, Rory N Gunson 11, Kate Templeton 12, Hamish Innes 3 2, Allan McLeod 2, Amanda Weir 2, Peter C Hayes 13, David Goldberg 3 2
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 331. | Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors |
| |
Prasad M1, Saade GR, Sandoval G, Hughes BL, Reddy UM, Mele L, Salazar A, Varner MW, Gyamfi-Bannerman C, Thorp JM Jr, Tita ATN, Swamy GK, Chien EK, Casey BM, Peaceman AM, El-Sayed YY, Iams JD, Gibbs RS, Sibai B, Wiese N, Kamili S, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Obstet Gynecol. 2020 Apr;135(4):778-788. doi: 10.1097/AOG.0000000000003754.
|
|
| |
| 332. | Reinfection following successful direct-acting antiviral therapy for hepatitis Cinfection among people who inject drugs |
| |
Cunningham EB1, Hajarizadeh B1, Amin J1,2, Hellard M3,4, Bruneau J5, Feld JJ6, Cooper C7, Powis J8, Litwin AH9, Marks P1, Dalgard O10, Conway B11, Moriggia A12,13, Stedman C14, Read P1,15, Bruggmann P16, Lacombe K17, Dunlop A18, Applegate TL1, Matthews GV1,19, Fraser C20, Dore GJ1,19, Grebely J1. Clin Infect Dis. 2020 Mar 12. pii: ciaa253. doi: 10.1093/cid/ciaa253. [Epub ahead of print]
|
|
| |
|
|
| |
| 334. | A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy |
| |
Akiyama MJ1, Lipsey D1, Ganova-Raeva L2, Punkova L2, Agyemang L1, Sue A2, Ramachandran S2, Khudyakov Y2, Litwin AH3. J Infect Dis. 2020 Mar 9. pii: jiaa100. doi: 10.1093/infdis/jiaa100. [Epub ahead of print]
|
|
| |
| 335. | Transplant Outcomes in Older Patients with Nonalcoholic Steatohepatitis Compared to Alcohol-Related Liver Disease and Hepatitis C |
| |
Henson JB1, Wilder JM2,3, Kappus MR2, Barbas AS4, Moylan CA2, Niedzwiecki D5, Muir AJ2,3, Berg CL2, Patel YA2. Transplantation. 2020 Mar 6. doi: 10.1097/TP.0000000000003219. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 340. | Examination of using alcohol to cope, depressive symptoms, and perceived social support in persons with HIV and Hepatitis C |
| |
Moitra E1, Anderson BJ2, Herman DS1,2, Hayaki J3, Pinkston MM1,4, Kim HN5,6, Stein MD7. AIDS Care. 2020 Feb 25:1-8. doi: 10.1080/09540121.2020.1734177. [Epub ahead of print]
|
|
| |
| 341. | Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care |
| |
Roberts K1, Macleod J1,2, Metcalfe C1,3, Hollingworth W1, Williams J4,5, Muir P6, Vickerman P1,2, Clement C2, Gordon F7, Irving W8, Waldron CA9, North P6, Moore P6, Simmons R5,10, Miners A4,5, Horwood J1,2, Hickman M11,2. BMJ. 2020 Feb 26;368:m322. doi: 10.1136/bmj.m322.
|
|
| |
| 342. | Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial |
| |
Horwood J1, Clement C2, Roberts K2, Waldron CA3, Irving WL4, Macleod J5, Hickman M6. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]Horwood J1, Clement C2, Roberts K2, Waldron CA3, Irving WL4, Macleod J5, Hickman M6. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]
|
|
| |
|
|
| |
| 344. | Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis CTreatment: A Randomized Controlled Trial |
| |
Davis JS1,2, Young M1, Marshall C3, Tate-Baker J3, Madison M3, Sharma S3, Silva C1, Jones T1, Davies J2,3. Open Forum Infect Dis. 2020 Jan 19;7(2):ofaa022. doi: 10.1093/ofid/ofaa022. eCollection 2020 Feb.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 348. | Hepatitis C Virus Vaccine: Challenges and Prospects |
| |
Duncan JD1,2,3, Urbanowicz RA1,2,3, Tarr AW1,2,3, Ball JK1,2,3. Vaccines (Basel). 2020 Feb 17;8(1). pii: E90. doi: 10.3390/vaccines8010090.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 356. | Hepatitis C Testing Among Perinatally Exposed Infants |
| |
Lopata SM1,2, McNeer E3,4, Dudley JA5, Wester C6, Cooper WO7,3,5, Carlucci JG7,8, Espinosa CM9,10, Dupont W4,5, Patrick SW7,2,3,5. Pediatrics. 2020 Mar;145(3). pii: e20192482. doi: 10.1542/peds.2019-2482. Epub 2020 Feb 14.
|
|
| |
|
|
| |
| 358. | Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R) |
| |
Schmitt A1, Günther R2, Mauss S3, Boeker KHW4, Buggisch P5, Hillenbrand H6, John C7, Klinker H8, Pathil A9,10, Simon KG11, Serfert Y12, Niederau C13, Vermehren J10, Wedemeyer H12,14,15, Sarrazin C1,10. Z Gastroenterol. 2020 Feb 10. doi: 10.1055/a-1068-3056. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 361. | A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program |
| |
Lee KS1,2, Quintiliani L1,3, Heinz A4, Johnson NL3, Xuan Z3, Truong V2, Lasser KE1,2,3. PLoS One. 2020 Feb 11;15(2):e0228767. doi: 10.1371/journal.pone.0228767. eCollection 2020
|
|
| |
| 362. | Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment |
| |
Kim NJ1, Pearson M1, Vutien P1, Su F1, Moon AM2, Berry K3, Green PK3, Williams EC3,4, Ioannou GN1,5. Hepatol Commun. 2020 Jan 2;4(2):314-324. doi: 10.1002/hep4.1464. eCollection 2020 Feb.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 366. | Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study |
| |
Adinolfi LE1, Petta S2, Fracanzani AL3, Coppola C4, Narciso V5, Nevola R6, Rinaldi L6, Calvaruso V2, Staiano L4, Di Marco V2, Marrone A6, Pafundi PC6, Solano A5, Lombardi R3, Sasso FC6, Saturnino M4, Rini F2, Guerrera B6, Troina G2, Giordano M6, Craxì A2. Atherosclerosis. 2020 Jan 21;296:40-47. doi: 10.1016/j.atherosclerosis.2020.01.010. [Epub ahead of print]
|
|
| |
| 367. | Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs |
| |
Rosenthal ES1,2, Silk R1,2, Mathur P1,2, Gross C1,2, Eyasu R1,2, Nussdorf L2,3, Hill K2,3, Brokus C2,3, D'Amore A2,3, Sidique N2,3, Bijole P4, Jones M4, Kier R4, McCullough D4, Sternberg D4, Stafford K1, Sun J3, Masur H2,3, Kottilil S1,2, Kattakuzhy S1,2. Clin Infect Dis. 2020 Feb 3. pii: ciaa105. doi: 10.1093/cid/ciaa105. [Epub ahead of print]
|
|
| |
|
|
| |
| 369. | Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, a service evaluation, the Hooked C project |
| |
Caven M1, Robinson EM1,2, Eriksen AJ3, Fletcher EH1,3, Dillon JF1,2. J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13269. [Epub ahead of print]
|
|
| |
| 370. | Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection |
| |
Scott N1,2, Snell G3, Westall G3, Pilcher D4,5, Raggatt M6,7, Walker RG8,9, Hellard M6,4,7, Peleg AY7,10, Doyle J6,7. Sci Rep. 2020 Jan 29;10(1):1459. doi: 10.1038/s41598-020-58215-z.
|
|
| |
|
|
| |
|
|
| |
| 373. | Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort |
| |
Soria A1, Fava M1,2, Bernasconi DP3, Lapadula G1, Colella E1, Valsecchi MG3, Migliorino GM1, D'Ambrosio R4, Landonio S5, Schiavini M5, Spinetti A6, Carriero C6, Degasperi E4, Cologni G7, Gatti F8, Viganò P8, Hasson H9, Uberti-Foppa C10, Pasulo L7, Baiguera C11, Rossotti R11, Vinci M11, Puoti M11, Giorgini A12, Menzaghi B13, Lombardi A14, Pan A15, Aghemo A16, Grossi PA17, Boldizzoni R18, Colombo S18, Viganò M19, Rumi MG19, Del Poggio P20, Valenti L21, Giglio O22, De Bona A12, d'Arminio Monforte A12, Colombo A22, Spinelli O22, Pigozzi MG6, Molteni C23, Bonfanti P23, Terreni N24, Perini P25, Capretti A26, Bella D27, Liani C27, Polo S27, Aimo G27, Pagnucco L14, Bhoori S28, Centenaro R29, Graffeo M30, Ciaccio A31, Dionigi E32, Lazzaroni S33, Carderi I34, Di Marco M35, Rizzardini G5, Noventa F36, Lampertico P4, Fagiuoli S7. Liver Int. 2020 Jan 22. doi: 10.1111/liv.14386. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 377. | Global prevalence of hepatitis C virus in children in 2018: a modelling study |
| |
Schmelzer J1, Dugan E1, Blach S1, Coleman S1, Cai Z1, DePaola M1, Estes C1, Gamkrelidze I1, Jerabek K1, Ma S1, Montoya S1, Razavi-Shearer D1, Razavi-Shearer K1, Robbins-Scott S1, Razavi H2, El Sayed MH3. Lancet Gastroenterol Hepatol. 2020 Jan 16. pii: S2468-1253(19)30385-1. doi: 10.1016/S2468-1253(19)30385-1. [Epub ahead of print]
|
|
| |
| 378. | Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in the TOPAZ-I and TOPAZ-II Trials |
| |
Poordad F1, Castro RE2, Asatryan A3, Aguilar H4, Cacoub P5,6, Dieterich D7, Marinho RT8, Carvalho A9, Siddique A10, Hu YB11, Charafeddine M12, Bondin M11, Khan N11, Cohen DE11, Felizarta F13. J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 386. | Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure |
| |
Chen Q1, Perales C1, Soria ME2, García-Cehic D1, Gregori J3, Rodríguez-Frías F4, Buti M1, Crespo J5, Calleja JL6, Tabernero D4, Vila M7, Lázaro F8, Rando-Segura A7, Nieto-Aponte L7, Llorens-Revull M1, Cortese MF7, Fernandez-Alonso I2, Castellote J9, Niubó J10, Imaz A11, Xiol X9, Castells L1, Riveiro-Barciela M1, Llaneras J1, Navarro J12, Vargas-Blasco V1, Augustin S1, Conde I13, Rubín Á13, Prieto M13, Torras X14, Margall N15, Forns X16, Mariño Z16, Lens S16, Bonacci M17, Pérez-Del-Pulgar S16, Londoño MC16, García-Buey ML18, Sanz-Cameno P18, Morillas R19, Martró E20, Saludes V20, Masnou-Ridaura H19, Salmerón J21, Quíles R21, Carrión JA22, Forné M23, Rosinach M23, Fernández I24, García-Samaniego J25, Madejón A25, Castillo-Grau P26, López-Núñez C27, Ferri MJ28, Durández R29, Sáez-Royuela F30, Diago M31, Gimeno C32, Medina R32, Buenestado J33, Bernet A34, Turnes J35, Trigo-Daporta M36, Hernández-Guerra M37, Delgado-Blanco M38, Cañizares A39, Arenas JI40, Gomez-Alonso MJ6, Rodríguez M41, Deig E42, Olivé G43, Río OD43, Cabezas J5, Quiñones I44, Roget M45, Montoliu S46, García-Costa J47, Force L48, Blanch S49, Miralbés M50, López-de-Goicoechea MJ51, García-Flores A52, Saumoy M11, Casanovas T9, Baliellas C9, Gilabert P9, Martin-Cardona A9, Roca R9, Barenys M53, Villaverde J9, Salord S9, Camps B9, Silvan di Yacovo M9, Ocaña I12, Sauleda S54, Bes M54, Carbonell J2, Vargas-Accarino E2, Ruzo SP2, Guerrero-Murillo M2, Von Massow G2, Costafreda MI55, López RM7, González-Moreno L18, Real Y18, Acero-Fernández D27, Viroles S27, Pamplona X27, Cairó M23, Ocete MD32, Macías-Sánchez JF43, Estébanez A5, Quer JC46, Mena-de-Cea Á38, Otero A38, Castro-Iglesias Á38, Suárez F38, Vázquez Á38, Vieito D38, López-Calvo S38, Vázquez-Rodríguez P38, Martínez-Cerezo FJ56, Rodríguez R47, Macenlle R47, Cachero A57, Mereish G57, Mora-Moruny C58, Fábregas S58, Sacristán B59, Albillos A60, Sánchez-Ruano JJ61, Baluja-Pino R62, Fernández-Fernández J62, González-Portela C62, García-Martin C63, Sánchez-Antolín G64, Andrade RJ65, Simón MA66, Pascasio JM67, Romero-Gómez M68, Antonio Del-Campo J68, Domingo E69, Esteban R1, Esteban JI70, Quer J71. Antiviral Res. 2019 Dec 16;174:104694. doi: 10.1016/j.antiviral.2019.104694. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 389. | Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C |
| |
Schlendorf KH1, Zalawadiya S1, Shah AS1, Perri R1, Wigger M1, Brinkley DM1, Danter MR1, Menachem JN1, Punnoose LR1, Balsara K1, Sacks SB1, Ooi H1, Awad JA1, Sandhaus E1, Schwartz C1, O'Dell H1, Carver AB1, Edmonds CL1, Ruzevich-Scholl S1, Lindenfeld J1. JAMA Cardiol. 2019 Dec 18. doi: 10.1001/jamacardio.2019.4748. [Epub ahead of print]
|
|
| |
| 390. | Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs |
| |
Irvin R1, Chander G1, Ward KM1, Manogue S1, Falade-Nwulia O1, Moon J1, Sutcliffe CG2, Brinkley S1, Haselhuhn T1, Katz S1, Herne K1, Arteaga L1, Thomas DL1, Mehta SH2, Sulkowski MS1. J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13251. [Epub ahead of print]
|
|
| |
| 391. | "Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy |
| |
Jessop AB1, Bass SB2, Brajuha J2, Alhajji M2, Burke M3, Gashat MT3, Wellington C2, Ventriglia N2, Coleman J2, D'Avanzo P2. J Subst Abuse Treat. 2020 Feb;109:23-33. doi: 10.1016/j.jsat.2019.11.001. Epub 2019 Nov 6.
|
|
| |
| 392. | Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study |
| |
Ferguson TF1,2, Rosen E1,2, Carr R3, Brashear M1,4, Simon L1,5, Theall KP1,4, Ronis MJ1,6, Welsh DA1,7, Molina PE1,5. Alcohol Alcohol. 2019 Dec 8. pii: agz089. doi: 10.1093/alcalc/agz089. [Epub ahead of print]
|
|
| |
|
|
| |
| 394. | Securing sustainable funding for viral hepatitis elimination plans |
| |
Hatzakis A1, Lazarus JV2, Cholongitas E3, Baptista-Leite R4,5, Boucher C6, Busoi CS7, Deuffic-Burban S8,9, Chhatwal J10, Esmat G11,12, Hutchinson S13,14, Malliori MM15, Maticic M16,17, Mozalevskis A18, Negro F19, Papandreou GA20, Papatheodoridis GV21, Peck-Radosavljevic M22, Razavi H23, Reic T24, Schatz E25, Tozun N26, Younossi Z27, Manns MP28. Liver Int. 2019 Dec 5. doi: 10.1111/liv.14282. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 397. | HCV NAT positive solid organ allografts transplanted into HCV negative recipients: A real-world experience |
| |
Kapila N1,2, Menon KVN3, Al-Khalloufi K4, Vanatta JM4, Murgas C4, Reino D4, Ebaid S4, Shaw JJ4, Agrawal N4, Rhazouani S4, Navas V4, Sheffield C4, Rahman AU1, Castillo M5, Miller C3, Quintini C3, Zervos XB4. Hepatology. 2019 Oct 28. doi: 10.1002/hep.31011. [Epub ahead of print]
|
|
| |
|
|
| |
| 399. | Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections |
| |
Dietz J1, Spengler U2, Müllhaupt B3, Schulze Zur Wiesch J4, Piecha F4, Mauss S5, Seegers B6, Hinrichsen H6, Antoni C7, Wietzke-Braun P8, Peiffer KH1, Berger A9, Matschenz K10, Buggisch P10, Backhus J11, Zizer E11, Boettler T12, Neumann-Haefelin C12, Semela D13, Stauber R14, Berg T15, Berg C16, Zeuzem S1, Vermehren J1, Sarrazin C17; European HCV Resistance Study Group. Clin Gastroenterol Hepatol. 2019 Nov 6. pii: S1542-3565(19)31260-1. doi: 10.1016/j.cgh.2019.10.051. [Epub ahead of print]
|
|
| |
|
|
| |
| 401. | The Elimination of Hepatitis C as a Public Health Threat |
| |
Hellard M1,2,3,4, Schroeder SE1,2, Pedrana A1,2, Doyle J1,3, Aitken C1,2. Cold Spring Harb Perspect Med. 2019 Nov 11. pii: a036939. doi: 10.1101/cshperspect.a036939. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 406. | Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis |
| |
Boyle A1,2, Marra F1,2, Peters E3, Datta S4, Ritchie T5, Priest M6, Heydtmann M7, Barclay ST8,9. J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13239. [Epub ahead of print]
|
|
| |
| 407. | Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies |
| |
Darvishian M1,2,3,4, Wong S1, Binka M1, Yu A1, Ramji A2, Yoshida EM5, Wong J1,2, Rossi C1,2, Butt ZA1,2, Bartlett S1,2, Pearce ME1,2, Samji H1,6, Cook D1, Alvarez M1, Chong M1, Tyndall M1,2, Krajden M1,2, Janjua NZ1,2. J Viral Hepat. 2019 Oct 30. doi: 10.1111/jvh.13228. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 410. | Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis Ctreatment for people who inject drugs: The HERO study |
| |
Litwin AH1, Jost J2, Wagner K3, Heo M4, Karasz A5, Feinberg J6, Kim AY7, Lum PJ8, Mehta SH9, Taylor LE10, Tsui JI11, Pericot-Valverde I12, Page K3; HERO Study Group. Contemp Clin Trials. 2019 Dec;87:105859. doi: 10.1016/j.cct.2019.105859. Epub 2019 Oct 24.
|
|
| |
|
|
| |
|
|
| |
| 413. | Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study |
| |
Bajis S1, Grebely J1, Hajarizadeh B1, Applegate T1, Marshall AD1,2, Harrod ME3, Byrne J4, Bath N3, Read P5, Edwards M6, Gorton C7, Hayllar J8, Cock V9, Peterson S10, Thomson C11, Weltman M12, Jefferies M13, Wood W14, Haber P15, Ezard N16,17, Martinello M1, Maher L1,18, Dore GJ1; LiveRLife Study Group. J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 417. | Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation |
| |
Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Transplantation. 2019 Oct 18. doi: 10.1097/TP.0000000000003014. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 423. | Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals |
| |
Serper M1, Evon DM2, Stewart PW3, Lok AS4, Amador J3, Reeve BB5, Golin CE6, Fried MW7, Reddy KR1, Sterling RK8, Sarkar S9, Di Bisceglie AM10, Lim JK11, Nelson DR12, Reau N13. J Gen Intern Med. 2019 Oct 28. doi: 10.1007/s11606-019-05394-9. [Epub ahead of print]
|
|
| |
| 424. | Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy |
| |
Cunningham EB1, Hajarizadeh B1, Amin J1,2, Litwin AH3,4,5, Gane E6, Cooper C7, Lacombe K8, Hellard M9,10, Read P1,11, Powis J12, Dalgard O13,14, Bruneau J15, Matthews GV1,16, Feld JJ17, Dillon JF18, Shaw D19, Bruggmann P20, Conway B21, Fraser C22, Marks P1, Dore GJ1,16, Grebely J1. Clin Infect Dis. 2019 Nov 2. pii: ciz1089. doi: 10.1093/cid/ciz1089. [Epub ahead of print]
|
|
| |
|
|
| |
| 426. | Glecaprevir/pibrentasvir for 8?weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial |
| |
Brown RS Jr1, Buti M2, Rodrigues L3, Chulanov V4, Chuang WL5, Aguilar H6, Horváth G7, Zuckerman E8, Carrion BR9, Rodriguez-Perez F10, Urbánek P11, Abergel A12, Cohen E3, Lovell SS3, Schnell G3, Lin CW3, Zha J3, Wang S3, Trinh R3, Mensa FJ3, Burroughs M3, Felizarta F13. J Hepatol. 2019 Nov 2. pii: S0168-8278(19)30647-6. doi: 10.1016/j.jhep.2019.10.020. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 431. | Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI?=?1 in a Single-Arm, Open-Label, Multicenter Study. |
| |
Fontana RJ1, Lens S2, McPherson S3, Elkhashab M4, Ankoma-Sey V5, Bondin M6, Dos Santos AGP6, Xue Z6, Trinh R6, Porcalla A6, Zeuzem S7. Adv Ther. 2019 Oct 23. doi: 10.1007/s12325-019-01123-0. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 437. | Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol) |
| |
Hickman M1, Dillon JF2, Elliott L3, De Angelis D4, Vickerman P5, Foster G6,7, Donnan P8, Eriksen A9, Flowers P3, Goldberg D3,10, Hollingworth W5, Ijaz S11, Liddell D12, Mandal S11, Martin N13, Beer LJZ14, Drysdale K6,7, Fraser H5, Glass R11, Graham L15, Gunson RN16, Hamilton E17, Harris H11, Harris M18, Harris R11, Heinsbroek E11, Hope V19, Horwood J5, Inglis SK14, Innes H3,10, Lane A5, Meadows J5, McAuley A3,10, Metcalfe C5, Migchelsen S11, Murray A17, Myring G5, Palmateer NE3,10, Presanis A4, Radley A2,20, Ramsay M11, Samartsidis P4, Simmons R11, Sinka K11, Vojt G3, Ward Z5, Whiteley D21, Yeung A3,10, Hutchinson SJ3,10. BMJ Open. 2019 Sep 24;9(9):e029538. doi: 10.1136/bmjopen-2019-029538.
|
|
| |
| 438. | Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016 |
| |
Zou B1, Yeo YH1, Le MH1, Henry L1, Chang ET2,3, Lok AS4, Cheung R1,5, Nguyen MH1. J Infect Dis. 2019 Sep 27. pii: jiz479. doi: 10.1093/infdis/jiz479. [Epub ahead of print]
|
|
| |
| 439. | Eradicating hepatitis C virus: The APRN |
| |
Pozza R1, McCoy-Hill C, Hall K, Hefner A, Wilgers K, Tapelband J, Masroor M, Hassanein T. Nurse Pract. 2019 Nov;44(11):16-27. doi: 10.1097/01.NPR.0000586008.23422.2c.
|
|
| |
| 440. | Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials |
| |
Brown A1, Welzel TM2, Conway B3, Negro F4, Bräu N5, Grebely J6, Puoti M7, Aghemo A8, Kleine H9, Pugatch D10, Mensa FJ10, Chen YJ10, Lei Y10, Lawitz E11, Asselah T12. Liver Int. 2019 Sep 30. doi: 10.1111/liv.14266. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 446. | Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline |
| |
Gordon CE1, Berenguer MC2, Doss W3, Fabrizi F4, Izopet J5, Jha V6, Kamar N7, Kasiske BL8, Lai CL9, Morales JM10, Patel PR11, Pol S12, Silva MO13, Balk EM14, Earley A15, Di M16, Cheung M15, Jadoul M17, Martin P18. Ann Intern Med. 2019 Sep 24. doi: 10.7326/M19-1539. [Epub ahead of print]
|
|
| |
| 447. | The case for a universal hepatitis C vaccine to achieve hepatitis C elimination |
| |
Scott N1,2, Wilson DP3,4, Thompson AJ5,6, Barnes E7,8, El-Sayed M9, Benzaken AS10, Drummer HE3,11,12, Hellard ME3,4,12,13. BMC Med. 2019 Sep 18;17(1):175. doi: 10.1186/s12916-019-1411-9.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 452. | Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-?G and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy |
| |
Emmanuel B1, El-Kamary SS2, Magder LS2, Stafford KA1,2, Charurat ME3, Chairez C4, McLaughlin M4, Hadigan C4, Prokunina-Olsson L5, O'Brien TR5, Masur H6, Kottilil S1. J Infect Dis. 2019 Aug 26. pii: jiz435. doi: 10.1093/infdis/jiz435. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 456. | HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study |
| |
Cooper CL1,2,3, Galanakis C4, Donelle J5, Kwong J5,6,7, Boyd R8, Boucher L9, Kendall CE4,5,9,10,11. BMC Infect Dis. 2019 Aug 23;19(1):712. doi: 10.1186/s12879-019-4315-6.
|
|
| |
|
|
| |
| 458. | Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care |
| |
McMahon BJ1,2, Townshend-Bulson L1, Homan C1, Gounder P2, Barbour Y1, Hewitt A1, Bruden D2, Espera H1, Plotnik J1, Gove J1, Stevenson TJ1, Luna SV1, Simons BC1,2. Clin Infect Dis. 2019 Aug 28. pii: ciz832. doi: 10.1093/cid/ciz832. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 461. | Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV |
| |
Saeed S1,2, Strumpf E1,3, Moodie EEM1, Wong L2, Cox J1,2, Walmsley S4,5, Tyndall M6, Cooper C5,7, Conway B8, Hull M5,9, Martel-Laferriere V10, Gill J11, Wong A12, Vachon ML13, Klein MB2,5; Canadian Co-Infection Cohort Study Investigators. Clin Infect Dis. 2019 Aug 28. pii: ciz833. doi: 10.1093/cid/ciz833. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 464. | Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C? |
| |
Ferrari SM1, Fallahi P2, Ruffilli I1, Elia G1, Ragusa F1, Paparo SR1, Patrizio A1, Mazzi V1, Colaci M3, Giuggioli D4, Ferri C4, Antonelli A1. J Immunol Res. 2019 Aug 8;2019:5878960. doi: 10.1155/2019/5878960. eCollection 2019.
|
|
| |
| 465. | Hepatitis C Core-Antigen Testing from Dried Blood Spots |
| |
Biondi MJ1,2,3, van Tilborg M4,5, Smookler D6,7, Heymann G8, Aquino A9, Perusini S10, Mandel E11,12, Kozak RA13, Cherepanov V14, Kowgier M15, Hansen B16,17, Goneau LW18, Janssen HLA19,20, Mazzulli T21,22, Cloherty G23, de Knegt RJ24, Feld JJ25,26,27. Viruses. 2019 Sep 6;11(9). pii: E830. doi: 10.3390/v11090830.
|
|
| |
|
|
| |
|
|
| |
| 468. | Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study |
| |
Trickey A1,2, Fraser H1, Lim AG1, Walker JG1, Peacock A3, Colledge S3, Leung J3,4,5, Grebely J5,6, Larney S3, Martin NK1,7, Degenhardt L3, Hickman M1,2, May MT1,2,8, Vickerman P1,2. J Viral Hepat. 2019 Aug 7. doi: 10.1111/jvh.13187. [Epub ahead of print]
|
|
| |
|
|
| |
| 470. | Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities |
| |
Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
|
|
| |
| 471. | Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study |
| |
Lee KK1, Stelzle D2, Bing R1, Anwar M1, Strachan F1, Bashir S1, Newby DE1, Shah JS3, Chung MH3, Bloomfield GS4, Longenecker CT5, Bagchi S6, Kottilil S6, Blach S7, Razavi H7, Mills PR8, Mills NL9, McAllister DA10, Shah ASV11. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):794-804. doi: 10.1016/S2468-1253(19)30227-4. Epub 2019 Jul 31.
|
|
| |
| 472. | We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade |
| |
Lazarus JV1, Pericàs JM2, Picchio C1, Cernosa J3, Hoekstra M1, Luhmann N4, Maticic M5,6, Read P7, Robinson EM8, Dillon JF8. J Intern Med. 2019 Aug 31. doi: 10.1111/joim.12972. [Epub ahead of print]
|
|
| |
| 473. | Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities |
| |
Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
|
|
| |
|
|
| |
|
|
| |
| 476. | Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study |
| |
Weinstein AA1, Estep JM2, de Avila L2, Curry M3, Golabi P2, Escheik C2, Birerdinc A2, Stepanova M4, Price JK2, Gerber L5, Younossi ZM6. J Neuroimmunol. 2019 Oct 15;335:577022. doi: 10.1016/j.jneuroim.2019.577022. Epub 2019 Aug 14.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 480. | Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities |
| |
Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
|
|
| |
|
|
| |
| 482. | Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population |
| |
Stevens ER1,2, Nucifora KA1, Hagan H2,3, Jordan AE3,4, Uyei J1, Khan B5, Dombrowski K5, des Jarlais D2, Braithwaite RS1,3. Clin Infect Dis. 2019 Aug 11. pii: ciz726. doi: 10.1093/cid/ciz726. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 485. | Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy |
| |
Lok AS1, Sulkowski MS2, Kort JJ3, Willner I4, Reddy KR5, Shiffman ML6, Hassan MA7, Pearlman BL8, Hinestrosa F9, Jacobson IM10, Morelli G11, Peter JA12, Vainorius M13, Michael LC14, Fried MW15, Wang GP16, Lu W17, Larsen L18, Nelson DR19. Gastroenterology. 2019 Aug 8. pii: S0016-5085(19)41199-2. doi: 10.1053/j.gastro.2019.08.008. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 490. | Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department |
| |
Hutton J1, Doyle J2, Zordan R3, Weiland T3, Cocco A4, Howell J5, Iser S6, Snell J7, Fry S8, New K8, Sloane R8, Jarman M7, Phan D7, Tran S7, Pedrana A9, Williams B9, Johnson J10, Glasgow S8, Thompson A7. Int J Drug Policy. 2019 Jul 24. pii: S0955-3959(19)30176-8. doi: 10.1016/j.drugpo.2019.06.021. [Epub ahead of print]
|
|
| |
| 491. | The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination |
| |
Safreed-Harmon K1, Blach S2, Aleman S3,4, Boe Kielland K5, Bollerup S6, Cooke G7, Dalgard O8,9, Dillon JF10, Dore GJ11, Duberg AS12, Grebely J11, Midgard H13, Porter K14, Razavi H2, Tyndall M15, Weis N6,16, Lazarus JV1,17. Clin Infect Dis. 2019 Jul 28. pii: ciz714. doi: 10.1093/cid/ciz714. [Epub ahead of print]
|
|
| |
| 492. | Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort |
| |
Macken L1,2, Gelson W3, Priest M4, Abouda G5, Barclay S4,6, Fraser A7, Healy B8, Irving W9, Verma S1,2. J Med Virol. 2019 Jul 22. doi: 10.1002/jmv.25552. [Epub ahead of print]
|
|
| |
| 493. | Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study |
| |
Rentsch CT1,2, Edelman EJ3,4, Justice AC5,3,4, Marshall BDL6, Xu K7, Smith AH7, Crystal S8, Gaither JR9,10, Gordon AJ11, Smith RV12, Kember RL13,14, Polimanti R7, Gelernter J7,15, Fiellin DA3,4, Tate JP5,3, Kranzler HR14,16, Becker WC3,10; VACS Project Team. AIDS Behav. 2019 Jul 17. doi: 10.1007/s10461-019-02608-3. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 497. | Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs |
| |
Barbosa C1, Fraser H2, Hoerger TJ1, Leib A3, Havens JR4, Young A4, Kral A1, Page K5, Evans J6, Zibbell J1, Hariri S7, Vellozzi C8, Nerlander L7, Ward JW7, Vickerman P2. Addiction. 2019 Jul 15. doi: 10.1111/add.14731. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 504. | Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study |
| |
Lanini S1, Bartolini B1, Taibi C1, Agresta A1, Garbuglia AR1, Montaldo C1, Pisapia R1, D'Offizi G1, Scognamiglio P1, Capobianchi MR1, Zumla A2, Ippolito G1. New Microbiol. 2019 Jul 15;42(2). [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 508. | Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners |
| |
Crowley D1,2, Murtagh R3, Cullen W3, Keevans M4, Laird E5, McHugh T6, McKiernan S7, Miggin SJ7, O'Connor E3,6, O'Reilly D4, Betts-Symonds G8, Tobin C9, Van Hout MC10, Lambert JS3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
|
|
| |
| 509. | HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center |
| |
Calner P1, Sperring H2, Ruiz-Mercado G3, Miller NS4, Andry C4, Battisti L5, Scrudder K3, Shea F3, Chan A3, Schechter-Perkins EM1. PLoS One. 2019 Jul 10;14(7):e0218388. doi: 10.1371/journal.pone.0218388. eCollection 2019.
|
|
| |
|
|
| |
|
|
| |
| 512. | Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners |
| |
Crowley D1,2, Murtagh R3, Cullen W3, Keevans M4, Laird E5, McHugh T6, McKiernan S7, Miggin SJ7, O'Connor E3,6, O'Reilly D4, Betts-Symonds G8, Tobin C9, Van Hout MC10, Lambert JS3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
|
|
| |
|
| | | | | |
